A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2016-08-01
Summary
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension is offered.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
- DRUG
-
MK0812
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Monitor · Merck Sharp & Dohme LLC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-08-31
- Primary Completion
- 2005-12-31
- Completion
- 2006-01-31
More Related Trials
-
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
NCT04834401 ·Status: COMPLETED
-
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316 ·Status: COMPLETED ·Phase: PHASE4
-
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
NCT00097331 ·Status: COMPLETED ·Phase: PHASE2
-
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
NCT05834855 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
NCT00420212 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2
-
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
NCT02845635 ·Status: COMPLETED
-
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
NCT00835770 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
NCT00219908 ·Status: TERMINATED ·Phase: PHASE2
-
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01838668 ·Status: COMPLETED ·Phase: PHASE3
-
ATX-MS-1467 in Multiple Sclerosis
NCT01973491 ·Status: COMPLETED ·Phase: PHASE2
-
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
NCT03872583 ·Status: COMPLETED ·Phase: NA
-
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
NCT01517282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
NCT05064436 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
NCT03085810 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
NCT07222956 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
COMparison Between All immunoTherapies for Multiple Sclerosis.
NCT03193866 ·Status: COMPLETED
-
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
NCT01051817 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
NCT04230174 ·Status: COMPLETED ·Phase: PHASE4
-
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
NCT00395317 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
NCT02472938 ·Status: WITHDRAWN ·Phase: PHASE4
-
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
NCT04742400 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT07189325 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)
NCT02301247 ·Status: COMPLETED ·Phase: NA
-
Assessment of Patients With Multiple Sclerosis (MS)
NCT00001156 ·Status: COMPLETED